St. Jude soars on CardioMEMS optimism; MedShape snags $11M;

@FierceMedDev: New special report: Med tech's hottest takeover targets for the rest of 2013. Feature | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics is expanding through a Peabody, MA acquisition (My old professional stomping grounds.) News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Alnylam posts positive PhI for RNAi cholesterol drug. Story from FierceDrugDelivery | Follow @MichaelGFierce

> St. Jude Medical's ($STJ) stock price soared to a 52-week high on optimism that the FDA will smile on investee CardioMEMS. Story

> Atlanta's MedShape locked down $11 million to develop and market its fixation devices for soft tissue repair. More

> As marketing efforts increase, rates of cases involving robotic surgery that damages patients are rising. Story

> Binder Biomedical's new stand-alone intervertebral body fusion device won 510(k) clearance from the FDA. Item

> A new study concludes that guidelines involving surgery after cardiac stent implantation should be loosened. Story

> Devicemaker Devon Medical is rolling out a new dressing to treat non-healing wounds on the toes and forefoot. Item

Biotech News

@FierceBiotech: Special Report: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Want to buy a million-square-foot monument to Merck's past glory? More | Follow @JohnCFierce

@DamianFierce: The FDA outlines its shutdown activities--nothing that hasn't been reported, but a handy document no less. More | Follow @DamianFierce

> Post-restructuring, Pfizer R&D focused on its top blockbuster prospects. More

> J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail. News

> Versartis nabs $20M to take growth hormone to PhIII. Story

> Bayer spotlights its late-stage pipeline contenders in cancer, cardio. Article

Pharma News

@FiercePharma: Trending this a.m. online: Forget drug-sales forecasts, study finds. They're usually wrong. Who does it best? Article | Follow @FiercePharma

@CarlyHFierce: From FierceVaccines: GlaxoSmithKline targeting a 2015 launch for its malaria vaccine. Report | Follow @CarlyHFierce

> Supreme Court asks DoJ for input on whistleblower evidence standards. Story

> Forget a Roche merger; Novartis sell-offs could be imminent, analyst says. Article

> WSJ: Doc clears Biogen Idec's Tecfidera in patient's death. News

Pharma Manufacturing News

@EricPFierce: Projecting $140M annual operating losses, Boehringer says Ben Venue plant not worth keeping open. Story | Follow @EricPFierce

> Aesica fined $161,000 for worker injury. Report

> Sartorius picking up TAP Biosystems in $45M deal. Story

> Recipharm, Fujifilm expand their biologics capabilities. Article

> Ranbaxy may look to buy FDA-approved plant in India. Item

Biotech Research News

@EmilyMFierce: There's a Major Foodborne Illness Outbreak and the Government's Shut Down. More from Wired | Follow @EmilyMFierce

> Three U.S.-based scientists jointly win Nobel Prize for cell transport discoveries. Article

> $6.25M grant establishes leukemia research initiative. Item

> Yale team investigates promising new class of antidepressants. Story

> Chemical in red wine kills cancer cells even after it's metabolized. More

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.